IDEAYA Biosciences Advances Phase 1/2 Trial for MTAP-Deleted Cancers with IDE892
Event summary
- IDEAYA Biosciences has initiated a Phase 1/2 clinical trial for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with IDE397 for MTAP-deleted pancreatic and lung cancers.
- Preclinical studies showed potent anti-tumor activity with complete and durable responses in MTAP-deleted tumor models.
- IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated in Q3 2026.
- MTAP deletion occurs in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC).
- IDEAYA has also entered a clinical collaboration with Roche to evaluate IDE892 in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor.
The big picture
IDEAYA Biosciences is positioning itself at the forefront of precision oncology by targeting MTAP-deleted cancers, a segment with no approved therapies. The company's strategy of enabling rational combinations with IDE892 and IDE397, along with its collaboration with Roche, underscores its commitment to delivering deeper and more durable responses for patients with pancreatic and lung cancers. The prevalence of MTAP deletion in these tumor types highlights a substantial market opportunity for IDEAYA's innovative approach.
What we're watching
- Clinical Trial Progress
- How the Phase 1/2 trial results will validate the efficacy and safety of IDE892 in combination with IDE397 for MTAP-deleted cancers.
- Strategic Collaborations
- Whether the collaboration with Roche will accelerate the development and commercialization of IDE892.
- Market Opportunity
- The pace at which IDEAYA can capitalize on the significant unmet need for therapies targeting MTAP-deleted cancers.
Related topics